Purpose: Co-mutations of the KRAS and STK11 genes in advanced non-small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. While neoadjuvant chemoimmunotherapy is now a standard of care treatment for resectable...
Conclusions: First results from a real-world population confirm promising efficacy of sotorasib for the treatment of advanced KRAS p.G12C-mutated NSCLC. Patients with co-occurring KEAP1 mutations seem to derive less benefit. 结论:来自真实人群的一...
In addition to the different mutation levels and mutation subtypes in different cancer tissues, KRAS mutations may have different comutations, which may influence the function of KRAS and the occurrence and development of tumours. Analysing 1078 NSCLCs harbouring KRAS mutations, 557 patients (53.5%)...
7. Arora S, Balasubramaniam S, Zhang H, et al. FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncologist2021;26(1):e164-e172.8. Luchini C, Brosens LAA, Wood LD, et al. Comprehensive charac...
Vaccination allows the KRAS-mutant tumor antigen to cause T cell responses, which has become a promising treatment. Both the T cell pools of healthy individuals and cancer patients contain T cells that can identify KRAS mutation. After vaccination those T cells can be selectively expanded in ...
Afatinib作为第二代广泛ERBB抑制剂,已经于2013年获美国FDA批准上市,用于治疗携带EGFR突变的转移性非小细胞肺癌(NSCLC)患者。2017年afatinib成功登陆中国,是首个在中国获批的第二代EGFR靶向药物。 如果afatinib等广泛的ERBB家族抑制剂,在后续的临床研究中,仍旧表现出如此优异的效果,无数的携带KRAS突变的患者将因此获益。
2024年3月28日,百时美施贵宝宣布,在3期临床试验 KRYSTAL-12 中,Adagrasib(KRAZATI)在具有KRASG12C突变的NSCLC患者的无进展生存期和总体缓解率方面带来了具有临床意义和统计学意义的益处。与化疗相比,这种药物降低了死亡或肿瘤进展的风险。 KRAZATI是一种高选择性和强效的KRAS G12C口服小分子抑制剂,具有长达24小...
tochemotherapyinthesecond-linetreatmentof patientswithcolorectalcancerwithKRASG12C mutation.Althoughadagrasibwasapprovedforuse asmonotherapyforNSCLCandshowedpreliminary antitumoractivityasmonotherapyinpatientswith colorectalcancerintheKRYSTAL-1Phase1/2trial,
FDA 批准了第二款 KRASG12C 抑制剂MRTX849(Adagrasib) 上市，都是用于治疗 KRASG12C 的 NSCLC ...
目前NSCLC的主要突变基因为致癌驱动突变,如表皮生长因子受体(epidermal growth factor receptor, EGFR)和膜相关的GTP酶信号传导蛋白KRAS(KRAS Proto-Oncogene,GTPase)突变[3]。针对EGFR 不同突变,已有上市的吉非替尼、阿法替尼、达克替尼等药物进行临床治疗。